TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19144392

Group type: EXPERIMENTAL
Intervention: NovaSil clay (high dose)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: NovaSil clay (low dose)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 177
Study: 18174931

Group type: EXPERIMENTAL
Intervention: Uncontrolled sideline environment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Controlled locker room environment
Number of subjects: 21
Study: 14709460

Group type: EXPERIMENTAL
Intervention: Continuous three‐in‐one femoral nerve block (FEM) with 30 mL ropivacaine 0.5% and epinephrine 1:200,000 bolus followed by an infusion of ropivacaine 0.2% at 12 mL/hr for 48 hr
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous posterior lumbar plexus (PSOAS) block with the same bolus and infusion regimen as the FEM group
Number of subjects: 60

Group type: COMPARATOR
Intervention: iv patient‐controlled morphine analgesia (PCA)
Number of subjects: 60
Study: 11826911

Group type: EXPERIMENTAL
Intervention: Loratadine syrup 5 mg or 10 mg daily for 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8956350

Group type: EXPERIMENTAL
Intervention: Racemic methadone (n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: l-methadone (n = 13)
Number of subjects: 26
Study: 14621848

Group type: EXPERIMENTAL
Intervention: CyG
Number of subjects: 10

Group type: COMPARATOR
Intervention: CyA
Number of subjects: 10
Study: 3887391

Group type: EXPERIMENTAL
Intervention: Cyclosporine (Cys) and prednisone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Azathioprine (Aza) and prednisone
Number of subjects: 43
Study: 31086287

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg rhCC10
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 5 mg/kg rhCC10
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 29972633

Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg with Cyclosporine 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Apixaban 10 mg with Tacrolimus 5 mg
Number of subjects: 12
Study: 26760084

Group type: EXPERIMENTAL
Intervention: Intensified treatment (higher-dose rifampin 15 mg/kg/day and levofloxacin 20 mg/kg/day for the first 8 weeks)
Number of subjects: 817

Group type: COMPARATOR
Intervention: Standard regimen (10 mg rifampin/kg/day for 9 months)
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Intensified treatment
Number of subjects: 817

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 817
Study: 24694949

Group type: EXPERIMENTAL
Intervention: Quality and Outcomes Framework (QOF) pay-for-performance program
Number of subjects: 110000
Study: 22554203

Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (AN) - single dose of four tablets on day 0
Number of subjects: 401

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DHP) - three to four tablets daily for three days
Number of subjects: 401
Study: 19088171

Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg + pemetrexed (500 mg/m2 i.v. every 21 days)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg + pemetrexed (500 mg/m2 i.v. every 21 days)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg + pemetrexed
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg + pemetrexed
Number of subjects: 21
Study: 17625917

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16449845

Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Combination of Nicotinic acid and Bezafibrate
Number of subjects: 83
Study: 12133363

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) in group B(1), n = 20
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group B(2), n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (group A, n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups post-CPB
Number of subjects: 60
Study: 9818786

Group type: EXPERIMENTAL
Intervention: 900 mg picotamide daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7714936

Group type: EXPERIMENTAL
Intervention: Chlorinated water
Number of subjects: 171

Group type: COMPARATOR
Intervention: Non-chlorinated water
Number of subjects: 171
Study: 2189867

Group type: EXPERIMENTAL
Intervention: Naltrexone hydrochloride (Trexan)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 35211

Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobazam 10 mg three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amylobarbitone sodium 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrazepam 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlordiazepoxide 10 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam 5 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31794244

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 168
Study: 28403662

Group type: EXPERIMENTAL
Intervention: Serum amyloid A (SAA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Soluble intercellular adhesion molecule 1 (sICAM‐1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Clinical pulmonary infection score (CPIS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combination of CPIS and SAA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 35
Study: 27632342

Group type: EXPERIMENTAL
Intervention: Hydrogel spacer injection before RT
Number of subjects: 167
Study: 26402319

Group type: EXPERIMENTAL
Intervention: Combination sedation (repeated bolus doses of fentanyl with propofol infusion)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conventional sedation (initial bolus of meperidine with propofol infusion)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Combination sedation
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conventional sedation
Number of subjects: 202
Study: 23867129

Group type: EXPERIMENTAL
Intervention: ARCON (Accelerated Radiotherapy combined with carbogen and nicotinamide)
Number of subjects: 272

Group type: COMPARATOR
Intervention: AR (Accelerated Radiotherapy)
Number of subjects: 272
Study: 21899733

Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement
Number of subjects: 31
Study: 19473534

Group type: EXPERIMENTAL
Intervention: Mentor mother support for up to 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17206293

Group type: COMPARATOR
Intervention: Transurethral resection of prostate (TURP)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Non-contact laser prostatectomy using ND: YAG laser at 40‐60 watt power and 13000‐29000 joules energy settings
Number of subjects: 87
Study: 15497670

Group type: EXPERIMENTAL
Intervention: Test formulation (30 mg pioglitazone hydrochloride)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Reference formulation (30 mg pioglitazone hydrochloride)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Test formulation and Reference formulation
Number of subjects: 26
Study: 11928567

Group type: EXPERIMENTAL
Intervention: Inhaled heparin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9466097

Group type: COMPARATOR
Intervention: Placebo injections pre- and intra-operatively (Group A)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Placebo pre-operatively and ketorolac 30 mg intra-operatively (Group B)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg pre-operatively and ketorolac 20 mg intra-operatively (Group C)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg pre-operatively and placebo intra-operatively (Group D)
Number of subjects: 137
Study: 7887164

Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution 5% applied prior to preoperative wash of the fornices with normal saline.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline wash immediately before surgery (Group A).
Number of subjects: 100
Study: 2895319

Group type: EXPERIMENTAL
Intervention: Phenprocoumon (60 patients)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No treatment (59 patients)
Number of subjects: 119
Study: 30894441

Group type: EXPERIMENTAL
Intervention: Fibrinolytic‐assisted hematoma evacuation
Number of subjects: 3386

Group type: COMPARATOR
Intervention: Control arms (various interventions)
Number of subjects: 3386
Study: 28298369

Group type: EXPERIMENTAL
Intervention: Intervention group (GDM risk factors)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Usual care group (GDM risk factors)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Early GDM group
Number of subjects: 289

Group type: COMPARATOR
Intervention: Healthy control group (no GDM risk factors)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Early GDM group compared to healthy control group
Number of subjects: 289
Study: 25433970

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine administered by male operators to female subjects
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine administered by female operators to male subjects
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine administered by male operators to male subjects
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine administered by female operators to female subjects
Number of subjects: 200
Study: 23607736

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (laser device switched off)
Number of subjects: 17
Study: 20110375

Group type: EXPERIMENTAL
Intervention: Multiple inflow pulsed arterial spin-labeling (ASL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 15
Study: 18628449

Group type: EXPERIMENTAL
Intervention: Multi-arm experimental treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Common control arm
Number of subjects: 0
Study: 16009478

Group type: EXPERIMENTAL
Intervention: Adults with Asperger's syndrome (AS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurotypical (NT) controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children with Asperger's syndrome (AS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurotypical (NT) controls (children)
Number of subjects: 0
Study: 12973834

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) - 2 cycles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-level laser therapy (LLLT) - 1 cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 10424376

Group type: EXPERIMENTAL
Intervention: Venous insufficiency diagnosed in men (14.6%) and women (33.6%)
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Varicose veins diagnosed in men (74.5%) and women (54.2%)
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Correlations found with sex, age, body mass index, and number of pregnancies
Number of subjects: 3065
Study: 8710750

Group type: EXPERIMENTAL
Intervention: Cetylpyridinium chloride in candy based lozenges
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aqueous solutions of the lozenges
Number of subjects: 6
Study: 1711614

Group type: EXPERIMENTAL
Intervention: Potassium supplementation (64 mmol/day)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Bendrofluazide (10 mg/day)
Number of subjects: 84
Study: 6354023

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (18 mg nebulized)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine sulphate (3 mg nebulized)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine sulphate (18 mg nebulized)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30874369

Group type: EXPERIMENTAL
Intervention: Aerobic resistance exercise intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Home-based exercise control
Number of subjects: 154
Study: 27773851

Group type: EXPERIMENTAL
Intervention: Intradermal allergen injections (7 ng of Phl p 5 major allergen)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Histamine control
Number of subjects: 93
Study: 27513252

Group type: EXPERIMENTAL
Intervention: Sevoflurane (5%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propofol (0.75 mg/kg iv)
Number of subjects: 24
Study: 24290345

Group type: EXPERIMENTAL
Intervention: Oligofructose/inulin 7 g/d
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 22
Study: 22122999

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin only once daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin + 20 mg famotidine twice daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole once daily
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg rabeprazole once daily
Number of subjects: 15
Study: 20149706

Group type: EXPERIMENTAL
Intervention: Exercise group (EXG, n=25) with self‐controlled exercise for at least 150 min/week and one additional supervised exercise session/week
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (COG, n=25) with no exercise instructions
Number of subjects: 50
Study: 17395869

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (balloon angioplasty or stenting)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 16
Study: 15802975

Group type: EXPERIMENTAL
Intervention: ddI + TDF
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: High ddI doses or taking a third NA
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Plasma levels of ddI
Number of subjects: 570

Group type: COMPARATOR
Intervention: Other NA combinations (including ddI or TDF separately)
Number of subjects: 570
Study: 11867504

Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine (NAC) 2 x 600 mg oral tablets
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 10464891

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 800 micrograms per day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8557242

Group type: EXPERIMENTAL
Intervention: Insulin analogue (B28Asp)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Actrapid HM
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both (B28Asp) and Actrapid HM
Number of subjects: 14
Study: 2183735

Group type: EXPERIMENTAL
Intervention: Needle with direct sonographic guidance
Number of subjects: 52

Group type: COMPARATOR
Intervention: Needle with catheter
Number of subjects: 52

Group type: COMPARATOR
Intervention: Needle only
Number of subjects: 52
Study: 396846

Group type: EXPERIMENTAL
Intervention: Madecassol
Number of subjects: 0
Study: 30973115

Group type: EXPERIMENTAL
Intervention: Tell Your Story (TYS) online stigma reduction intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 103
Study: 31006728

Group type: EXPERIMENTAL
Intervention: Ethyl icosapentate (EPA) 1.8 g t.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: EPA+DHA 2 g s.i.d.
Number of subjects: 0
Study: 27935767

Group type: EXPERIMENTAL
Intervention: HE+PA
Number of subjects: 436

Group type: COMPARATOR
Intervention: HE
Number of subjects: 436

Group type: COMPARATOR
Intervention: PA
Number of subjects: 436

Group type: COMPARATOR
Intervention: UC
Number of subjects: 436
Study: 26281201

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment and azathioprine 2 mg/kg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with azathioprine 2 mg/kg/day, hormone ointment 1 mg/day, and metronidazole suppositories 250 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PCDAI scores in the study group
Number of subjects: 20

Group type: COMPARATOR
Intervention: PCDAI scores in the control group
Number of subjects: 20
Study: 23794338

Group type: EXPERIMENTAL
Intervention: Clarithromycin, amoxicillin, and omeprazole
Number of subjects: 165

Group type: COMPARATOR
Intervention: Azithromycin, amoxicillin, and omeprazole
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Clarithromycin, amoxicillin, and omeprazole (subgroup with peptic ulcer disease)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Azithromycin, amoxicillin, and omeprazole (subgroup with peptic ulcer disease)
Number of subjects: 165
Study: 21784839

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ARB (100 mg/d losartan)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ARB plus diuretics (100 mg/d losartan plus 25 mg/d hydrochlorothiazide)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Regular and low sodium diets (193 ± 62 versus 93 ± 52 mmol Na(+)/d)
Number of subjects: 33
Study: 19338552

Group type: EXPERIMENTAL
Intervention: Retrograde ureteroscopy and holmium:YAG laser lithotripsy
Number of subjects: 164

Group type: COMPARATOR
Intervention: Extracorporeal shockwave lithotripsy (ESWL)
Number of subjects: 164
Study: 17152394

Group type: EXPERIMENTAL
Intervention: infant‐parent psychotherapy (IPP)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: psychoeducational parenting intervention (PPI)
Number of subjects: 137

Group type: COMPARATOR
Intervention: community standard (CS)
Number of subjects: 137

Group type: COMPARATOR
Intervention: nonmaltreating families (NC)
Number of subjects: 137
Study: 15103878

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Expectant management with bleeding at inclusion
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Expectant management without bleeding but with a non-viable pregnancy
Number of subjects: 188
Study: 10954001

Group type: EXPERIMENTAL
Intervention: Aspirin D,L-lysine (18 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 12
Study: 9197046

Group type: EXPERIMENTAL
Intervention: Rooming-in
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 8243524

Group type: EXPERIMENTAL
Intervention: Pentaglobin (IgM-enriched intravenous immunoglobulin)
Number of subjects: 1000
Study: 3514727

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 533

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 533
Study: 30095659

Group type: EXPERIMENTAL
Intervention: Prophylactic infusion of phenylephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 60
Study: 27751846

Group type: EXPERIMENTAL
Intervention: Regorafenib (160 mg per day, 3 weeks on and 1 week off)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 182
Study: 24916203

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) imaging with septal flash (SF) assessment
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Absence of myocardial scar combined with presence of SF
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Presence of SF
Number of subjects: 52
Study: 22397215

Group type: EXPERIMENTAL
Intervention: Sodium enoxaparin treatment for 10 days, followed by an additional 10 days after a 10-day no treatment period.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 60
Study: 20546462

Group type: EXPERIMENTAL
Intervention: Intravenous plus oral iron (single intravenous iron polymaltose infusion + daily oral ferrous sulphate 250 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral iron only (daily oral ferrous sulphate 250 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intravenous plus oral iron
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral iron only
Number of subjects: 200
Study: 18192624

Group type: EXPERIMENTAL
Intervention: After-school treatment program (10-week duration)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Community comparison (control group)
Number of subjects: 23
Study: 16152836

Group type: EXPERIMENTAL
Intervention: Hailong Juanxiao Recipe combined with Kechuanping sticking on Yongquan acupoint (HKSYA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Western medicine (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: HKSYA
Number of subjects: 150
Study: 15589088

Group type: EXPERIMENTAL
Intervention: Oral methadone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Usual opioid (control)
Number of subjects: 6
Study: 11759825

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg/day
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg/every other day
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Tamoxifen (all doses)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 9149991

Group type: EXPERIMENTAL
Intervention: Combined use of hyaluronidase and methylprednisolone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Instillation of methylprednisolone alone
Number of subjects: 70
Study: 7956335

Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2962597

Group type: EXPERIMENTAL
Intervention: MRI with Gd‐DTPA (MRI+)
Number of subjects: 50

Group type: COMPARATOR
Intervention: MRI without Gd
Number of subjects: 50

Group type: COMPARATOR
Intervention: CT with intravenous contrast enhancement
Number of subjects: 50
Study: 31707860

Group type: EXPERIMENTAL
Intervention: SNF472 300 mg
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: SNF472 600 mg
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 29174303

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study: 27836011

Group type: EXPERIMENTAL
Intervention: Unilateral ECT
Number of subjects: 147

Group type: COMPARATOR
Intervention: Non-ECT
Number of subjects: 147
Study: 24824633

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg twice a day
Number of subjects: 167

Group type: COMPARATOR
Intervention: Glimepiride 2 mg three times a day
Number of subjects: 167